Komori
Governance4582SymBio Pharmaceuticals LimitedPharmaceuticals

Corporate Governance Report 2026/04/01

The report sets out the company’s organizational structure as a company with an Audit and Supervisory Committee, as well as the framework for the Nomination and Compensation Committee and other committees. There are 5 directors excluding Audit and Supervisory Committee members and 3 Audit and Supervisory Committee members. Of the 7 outside directors in total, 4 can be identified as such.

Worth reading
74In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directorsTotal of 8 directors, including 4 outside directors out of 7 (4 outside directors among the 5 directors excluding Audit and Supervisory Committee members; the number of outside Audit and Supervisory Committee members is not disclosed)
Committee4
Nomination and Compensation CommitteeAudit and Supervisory CommitteeInternal Control Committeeand Compliance Committee. The proportion of outside members is not disclosed.
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directorsTotal of 8 directors, including 4 outside directors out of 7 (4 outside directors among the 5 directors excluding Audit and Supervisory Committee members; the number of outside Audit and Supervisory Committee members is not disclosed)
CommitteeNomination and Compensation Committee, Audit and Supervisory Committee, Internal Control Committee, and Compliance Committee. The proportion of outside members is not disclosed.
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Not stated.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/04/01 | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori